DDN editorial team
The DDN Editorial team includes: Senior Editor, Andrea Corona, Associate Editor, Allison Whitten, PhD, and Assistant Editor, Bree Foster, PhD.Content by DDN editorial team
| 4 min read
Greater focus on non-animal testing methods in the UK, a new CRISPR treatment to lower cholesterol, and positive results for a BTK inhibitor in MS led the news this week.
| 4 min read
Another biotech retreats from AAV, a promising antibiotic, a paused CRISPR trial, and more led the news this week.
| 4 min read
Multibillion dollar oncology deals, first-in-class wins, AI scientists, and more led the news this week.
| 4 min read
Positive results for breast cancer, funding for precision therapies for heart disease, strong results for Lilly’s oral GLP-1, and more led the news this week.
| 4 min read
Positive results for a radioligand therapy, a billion-dollar deal for a MASH drug, the Nobel Prize for immune system research, and more led the news this week.
| 4 min read
An FDA rejection, Takeda restructuring, Trump initiatives and more lead the news this week.
| 3 min read
Promising new therapies for Huntington’s disease and multiple myeloma, the first FDA approval for Barth syndrome, and more led the news this week.
| 4 min read
New results from an anti-seizure medication and blood cancer drug, a new AI platform, and a novel heart disease drug led drug discovery this week.
| 4 min read
Vertex-Enlaza autoimmune drugs, DNA-wrapped CRISPR, HHS staff demand Kennedy’s resignation, and more lead the news this week.
| 3 min read
Oral GLP-1 data, srRNA therapies, and decentralized CAR T led drug discovery this week.
| 4 min read
In vivo CAR T, lab-grown eggs, trial access, postpartum depression, and RNA therapy for hereditary angioedema led drug discovery this week.
| 4 min read
Sepsis antibody breakthroughs, a billion-dollar KRAS deal, and FDA’s push to rebuild domestic drug manufacturing led the drug discovery news this week.
